References
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 : 2391–405.
2. Julia F, Dalle S, Duru G, et al. Blastic plasmacytoid dendritic cell neoplasms: Clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 2014; 38 : 673–80.
3. Venugopal S, Zhou S, El Jamal SM, Lane AA, Mascarenhas J. Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights. Clin Lymphoma, Myeloma Leuk 2019; 19 : 545–54.
4. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: Diagnostic criteria and therapeutical approaches. Br J Haematol 2016; 174 : 188–202.
5. Martín-Martín L, López A, Vidriales B, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile.Oncotarget 2015; 6 : 19204–16.
6. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural Killer (NK)/T-cell lymphoma, nasal type: The NK-cell tumor study group study. J Clin Oncol 2011; 29 : 4410–6.
7. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med 2013; 25 : 2379–90.
8. Nakao K, Oka S, Utsumi T, et al. [Concurrent CALR and SF3B1 gene mutations in a patient with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis]. Rinsho Ketsueki 2019; 60 : 915–9.
9. Taylor J, Haddadin M, Upadhyay VA, et al. Multicenter Analysis of Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm Offers a Pre-Targeted Therapy Benchmark. Blood 2019; 134 : 678–87.
10. Sakamoto K, Katayama R, Asaka R, et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia 2018; 32 : 2590–603.
11. Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An italian multicenter study. Haematologica 2013; 98 : 239–46.
12. Suzuki R. NK/T-cell lymphomas: Pathobiology, prognosis and treatment paradigm. Curr Oncol Rep 2012; 14 : 395–402.
13. Sugimoto KJ, Shimada A, Yamaguchi N, et al. Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a simultaneous combination of low-dose DeVIC therapy and radiation therapy: A case report and review of the literature. Int J Clin Exp Pathol 2013; 6 : 2603–8.
14. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol 2010; 149 : 578–86.